In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Gender differences in achieving the minimum clinically important difference in the incremental shuttle walk test in coronary artery bypass graft patients

Session Time to go to rehab - Best of cardiac rehabilitation

Speaker Jassas Alotaibi

Event : ESC Congress 2017

  • Topic : preventive cardiology
  • Sub-topic : Rehabilitation: Outcomes
  • Session type : Moderated Posters

Authors : J Alotaibi (York,GB), P Doherty (York,GB)

Authors:
J. Alotaibi1 , P. Doherty1 , 1University of York, Health Sciences - York - United Kingdom ,

Citation:
European Heart Journal ( 2017 ) 38 ( Supplement ), 1031

Background: The improvement of cardiorespiratory fitness is one of the primary goals of Cardiac Rehabilitation (CR). In the UK, the Incremental Shuttle Walk Test (ISWT) is the most widely used field test to assess cardiorespiratory fitness in CR patients. Previous studies show that CR improves cardiorespiratory fitness, however, there is a lack of research into the difference in the change in fitness as a result of CR between males and females, particularly in post-CABG patients in the UK.

Purpose: The aim of the study was to evaluate the extent of change in the ISWT distance achieved by post-CABG males and females and to compare the likelihood of males and females achieving the minimum clinically important difference (MCID) of 70m.

Methods: A retrospective study used data from the National Audit Cardiac Rehabilitation (NACR) collected between April 2013 and December 2016 from 48 CR centres. The participants were included if they were ≥18 years and had completed their ISWT prior to and following their CR programme as a cardiorespiratory fitness assessment. Independent t-tests and Chi-square tests were used to compare the baseline results of the males and females as appropriate. Multiple linear regression was used to compare the change in ISWT distances between the two groups taking account of age and ISWT baseline measurement and other potential confounders namely BMI; height; weight; presence of hypertension or diabetes; smoking; and physical activity level based on 150 minutes per week of moderate activity. Binary logistic regression was used to investigate the likelihood of achieving the MCID controlling for the potential confounders and odds ratios (OR) were calculated as an affect size. Due to the nested nature of the data coming from 48 centres, the Huber-White sandwich estimator was used. A P-value of <0.05 is considered to be significant. The analyses were conducted using STATA V.13.1.

Results: A total of 1,899 CR outpatients (males 1621 and females 278) ranged in age from 24 to 99 years with a mean age of 66.2 (± 9.56) years for males and 67.6 (± 9.15) years for females. By adjusting for the other variables, the difference in the mean change in the distance walked between males and females was 33m (110m Vs 77m, p<0.001). Males were also twice as likely as females to achieve the MCID (70m) (OR 2, 95% CI 1.60– 2.67, p<0.001).

Conclusion: The MCID of 70m lacks relevance for female patients and so a gender specific MCID value is required.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are